These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14576660)

  • 1. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
    Ball RA; Kinchelow T;
    J Am Acad Dermatol; 2003 Nov; 49(5):826-31. PubMed ID: 14576660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA; Turiansky GW
    J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
    Rice C; Wilantewicz H
    AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localized amyloidosis at the site of enfuvirtide injection.
    Morilla ME; Kocher J; Harmaty M
    Ann Intern Med; 2009 Oct; 151(7):515-6. PubMed ID: 19805777
    [No Abstract]   [Full Text] [Related]  

  • 5. Enfuvirtide injection site reactions: a clinical and histopathological appraisal.
    Wallace BJ; Tan KB; Pett SL; Cooper DA; Kossard S; Whitfeld MJ
    Australas J Dermatol; 2011 Feb; 52(1):19-26. PubMed ID: 21332688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fuzeon-induced collagenophagic granuloma: a peculiar granulomatous injection site reaction to Fuzeon--a case report and review of literature.
    Sidhu HK; Chaffee BH; Tvetenstrand CD; Sidhu JS
    Int J Surg Pathol; 2010 Oct; 18(5):384-7. PubMed ID: 19223380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
    Jamjian MC; McNicholl IR
    Am J Health Syst Pharm; 2004 Jun; 61(12):1242-7. PubMed ID: 15259753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction.
    Shahar E; Moar C; Pollack S
    AIDS; 2005 Mar; 19(4):451-2. PubMed ID: 15750403
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful desensitization of enfuvirtide after a first attempt failure.
    Machado ES; Passoni LF; Sidi LC; Andrade HB; De Menezes JA
    AIDS; 2006 Oct; 20(16):2130-1. PubMed ID: 17053365
    [No Abstract]   [Full Text] [Related]  

  • 10. Enfuvirtide (T-20): potentials and challenges.
    Foy K; Juethner SN
    J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
    Oates E; Dzintars K
    Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E; Becić F; Zvizdić S
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse of intravenous drug use triggered by enfuvirtide, a parenteral antiretroviral medication.
    Avelino-Silva VI; Li HY; Novaes CT
    AIDS Patient Care STDS; 2012 Feb; 26(2):71-2. PubMed ID: 22148866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
    Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
    Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
    Raffi F
    Med Mal Infect; 2004 Sep; 34 Spec No 1():8-17. PubMed ID: 15742550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.
    Church JA; Hughes M; Chen J; Palumbo P; Mofenson LM; Delora P; Smith E; Wiznia A; Hawkins E; Sista P; Cunningham CK;
    Pediatr Infect Dis J; 2004 Aug; 23(8):713-8. PubMed ID: 15295220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.
    Clotet B; Raffi F; Cooper D; Delfraissy JF; Lazzarin A; Moyle G; Rockstroh J; Soriano V; Schapiro J
    AIDS; 2004 May; 18(8):1137-46. PubMed ID: 15166529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enfuvirtide: a new class of antiretroviral therapy for HIV infection.
    Leao JC; Frezzini C; Porter S
    Oral Dis; 2004 Nov; 10(6):327-9. PubMed ID: 15533206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
    Myers SA; Selim AA; McDaniel MA; Hall R; Zhang Y; Bartlett JA; True AL
    Antivir Ther; 2006; 11(7):935-9. PubMed ID: 17302257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.